Ra Medical Systems Launches Cardiovascular and Dermatology Catheters and Lasers in Northern Europe
Ra Medical Systems, makers of excimer lasers and catheters for cardiovascular and dermatological diseases, and bo medical technologies, a multinational medical device sales and service distributor, announce the launch of the DABRA Atherectomy System for cardiovascular and Pharos Excimer Laser for dermatology in Europe.
Ra Medical’s Pharos (FDA market cleared and CE mark) has more than a decade of success treating challenging, chronic dermatology diseases including psoriasis, vitiligo, and atopic dermatitis throughout the United States, Middle East, and Asia. The DABRA Atherectomy System (CE mark, Investigational in the United States), has a 95% success rate in clinical trials in North America.
“Bo medical technologies has extensive expertise and market presence in both dermatology and vascular markets in the Benelux Union as well as Scandinavia. They have outstanding relationships with thought leaders and high volume practitioners in both therapeutic areas, extensive technical experience, and the drive to capture the Northern European market for both Pharos and DABRA,” said Ra Medical Systems Co-Founder and CEO Dean Irwin.
“We see bo medical as the first of many successful partnerships as we penetrate the dermatology and vascular markets in Europe. We are actively looking for additional distribution partners throughout Europe as we drive Pharos’ and DABRA’s commercialization in this region,” added Mr. Irwin.
Henk-Peter Oonk, MD, CEO of bo medical technologies commented, “Pharos will have a significant impact because all the doctors will market this to their patients as another option in the treatment of psoriasis and vitiligo. Biologicals are burdensome to some patients and not everybody desires or are eligible for them. Pharos will be a major breakthrough in the treatment of psoriasis and vitiligo in Europe.”
“Healthcare continues to evolve, with practitioners looking for newer, more cost-effective, safer, and better options than current treatments. Our laser and catheter systems offer alternative treatment options with potentially better outcomes and are now available in markets around the world. Giving patients access to these treatments for their diseases, often for the first time in their lives, is quite rewarding,” added Jeffrey Kraws, President.
About Ra Medical Systems
Ra Medical Systems was founded in 2002 to commercialize excimer
lasers for the treatment of dermatologic and cardiovascular diseases.
Its flagship product, Pharos, launched in 2004 and revolutionized the
dermatology world with its technology and game-changing business model.
Today, Ra Medical Systems continues to make history as it commercializes the DABRA catheter and laser cardiovascular system.
About bo medical technologies
Bo medical technologies engages in exclusive distribution and sales of cosmetic and vascular technology products. The company looks at cosmetic care from a medical perspective and seeks products whose effects are beyond dispute and published in leading medical journals. The portfolio consists of breakthrough devices and products for dermatologists and plastic surgeons as well as cardiologists.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described here may contain forward-looking statements, including statements that involve risk and uncertainties that may individually or mutually impact the matters herein and cause actual results, events and performance to differ materially.
Ra Medical Systems
Jeffrey Kraws, President
Internationally: +1 760 804 1648
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IPSEN16.1.2018 23:08 | pressemeddelelse
Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma
NY-IFF16.1.2018 22:18 | pressemeddelelse
IFF to Release Fourth Quarter & Full Year 2017 Results February 14
CA-PATIENT-SAFETY-MVMNT16.1.2018 20:19 | pressemeddelelse
President Clinton to Address Healthcare Leaders Focused on Eliminating Preventable Deaths in Hospitals at the 6th Annual World Patient Safety, Science & Technology Summit
DISARONNO16.1.2018 17:08 | pressemeddelelse
Disaronno: The Mixing Star Makes a Step Change and Looks to Innovation
NY-CHRISTIE’S16.1.2018 16:57 | pressemeddelelse
Christie’s Announces Public Preview Tour Dates for The Collection of Peggy and David Rockefeller
MA-CONTINUUM16.1.2018 16:02 | pressemeddelelse
Continuum Accelerates Global Expansion with Portland Europe
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum